For research use only. Not for therapeutic Use.
Vepsitamab (Cat No.: I042132) is an investigational monoclonal antibody developed to target CD123, the interleukin-3 receptor alpha chain, which is overexpressed on leukemic stem cells and blasts in acute myeloid leukemia (AML) and other hematologic malignancies. By binding to CD123, vepsitamab facilitates immune-mediated cell killing, particularly through antibody-dependent cellular cytotoxicity (ADCC). It is being evaluated for its potential to eliminate malignant cells while sparing normal hematopoietic stem cells. Vepsitamab represents a promising therapeutic approach in precision oncology targeting leukemia-associated antigens.
| CAS Number | 2413453-53-7 |
| Purity | ≥95% |
| Reference | [1]. Joseph Chao, et al. Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. 2020 ASCO Annual Meeting I. |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
